Cencora, Inc. (NYSE:COR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Cencora, Inc. (NYSE:COR) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $399.00.

A number of equities analysts recently commented on the company. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Barclays upped their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Finally, UBS Group upped their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th.

Cencora Price Performance

Shares of COR opened at $359.98 on Wednesday. The firm has a market cap of $70.03 billion, a PE ratio of 43.27, a P/E/G ratio of 1.66 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora has a 1-year low of $237.71 and a 1-year high of $377.54. The firm has a fifty day simple moving average of $348.42 and a two-hundred day simple moving average of $329.91.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the prior year, the company earned $3.73 earnings per share. Cencora’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts anticipate that Cencora will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio is presently 28.85%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 15,220 shares of company stock worth $5,282,867 over the last three months. 0.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in Cencora in the fourth quarter worth $25,000. Oakworth Capital Inc. purchased a new stake in Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the fourth quarter worth $27,000. Finally, Archer Investment Corp grew its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.